The information in this section is intended for visitors outside the United States.
Gilead actively supports investigator-sponsored research conducted by third parties on Gilead's marketed products or within therapeutic areas of interest to the company. This research can provide valuable information regarding the safety, efficacy, pharmacology, and tolerability of Gilead's products and supplement the comprehensive data generated in registration studies.
If you are interested in applying for support for investigator-sponsored research, please review the submission process and apply online.
Gilead provides grants primarily in our therapeutic areas of expertise and based on the scientific merit of the proposal. The research must be intended to contribute knowledge to the medical community. The budget must be reasonable and appropriate for the proposed work. In considering applications for support, Gilead will also consider the expertise of the proposed principal investigator and any sub-investigators, including their experience in the relevant therapeutic area, demonstrated ability to successfully conduct clinical trials, and available resources.
Your proposal will be considered by one or more cross-functional committees that meet routinely to review ISR proposals. Gilead may make suggestions to improve the scientific merit of the proposal and enhance consistency with Gilead's support approval criteria described above, although as the study sponsor, the principal investigator will have full and final discretion and responsibility for all aspects of the study design, implementation, data analysis, and data dissemination, including compliance with all laws and regulations applicable to research sponsors. The terms under which Gilead will provide support must be contained in a written agreement. Gilead provides no guarantees that it will provide support for your proposal.
To apply for a research grant, please click below. The form must be completed in full and is required in order to help us evaluate your grant request.